US neurology最新文献_第5页

Cenobamate for the Treatment of Focal Seizures 治疗局灶性癫痫

US neurology Pub Date : 2020-01-01 DOI: 10.17925/USN.2020.16.2.87

P. Klein, Louis Ferrari, W. Rosenfeld, Mid-Atlantic Epilepsy, St. Louis Mo Usa Adults

{"title":"Cenobamate for the Treatment of Focal Seizures","authors":"P. Klein, Louis Ferrari, W. Rosenfeld, Mid-Atlantic Epilepsy, St. Louis Mo Usa Adults","doi":"10.17925/USN.2020.16.2.87","DOIUrl":"https://doi.org/10.17925/USN.2020.16.2.87","url":null,"abstract":"Epilepsy is a common neurological disease. Anti-seizure medication (ASM) is the first-line treatment, beginning with monotherapy and, in uncontrolled epilepsy, progressing to combination therapy over time, with the goal of seizure freedom. Cenobamate is an oral ASM approved for the treatment of focal (partial-onset) seizures in adults. Two clinical studies (C013, C017) evaluated adjunctive cenobamate in uncontrolled focal epilepsy despite treatment with one to three ASMs. In C013, cenobamate 200 mg/day, and in C017, cenobamate 100, 200, and 400 mg/day reduced seizure frequency by 55.6%, 35.5%, 55.0%, and 55.0%, respectively. Up to 20% more cenobamate-treated (C013: 200 mg/day, C017: 400 mg/day) patients achieved zero seizures versus placebo during the maintenance phase of therapy. Three cases of drug reaction with eosinophilia and systemic symptoms, including one fatality, were reported during clinical development with starting doses ≥50 mg/day and weekly up-titration. Safety data from C013, C017, and an open-label safety study (C021), demonstrated the most common adverse events associated with cenobamate were central nervous system-related. Given the efficacy and seizure-free rates, along with the side effect profile confirmed in C021 with a lower initial dose and slower up-titration every 2 weeks, cenobamate is a potentially important addition to currently available ASMs.","PeriodicalId":90076,"journal":{"name":"US neurology","volume":"16 1","pages":"87"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67612267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Rational Prescribing with an Individualized Approach to Therapy for the Prevention of Migraine 合理处方与个体化治疗方法预防偏头痛

US neurology Pub Date : 2020-01-01 DOI: 10.17925/usn.2020.16.1.15

J. Rothrock, Ira M Turner, J. Brandes

引用次数: 1

The Upper Nasal Space—A Novel Delivery Route Ideal for Central Nervous System Drugs 上鼻空间——中枢神经系统药物理想的新递送途径

US neurology Pub Date : 2020-01-01 DOI: 10.17925/usn.2020.16.1.25

J. Hoekman, Sutapa Ray, S. Aurora, S. Shrewsbury

引用次数: 13

Diagnosis and Management of New Onset Epilepsy in Adults 成人新发癫痫的诊断和治疗

US neurology Pub Date : 2020-01-01 DOI: 10.17925/usn.2020.16.1.32

Anna M. Bank, R. Kuzniecky

引用次数: 0

Anabolic Androgenic Steroid Abuse and Cerebral Venous Thrombosis—A Case Report 合成代谢雄激素类固醇滥用与脑静脉血栓形成一例报告

US neurology Pub Date : 2020-01-01 DOI: 10.17925/USN.2020.16.2.120

Marlene Saraiva, J. Marto, A. Correia, M. Baptista

引用次数: 1

A Retrospective Review to Evaluate the Demographics and Management Profile of Patients with Amyotrophic Lateral Sclerosis Attending a Multidisciplinary Clinic 参加多学科诊所的肌萎缩侧索硬化症患者的人口统计学和管理概况的回顾性评价

US neurology Pub Date : 2020-01-01 DOI: 10.17925/USN.2020.16.2.110

Arash Jalali-Sohi, L. Darki, S. Beydoun

{"title":"A Retrospective Review to Evaluate the Demographics and Management Profile of Patients with Amyotrophic Lateral Sclerosis Attending a Multidisciplinary Clinic","authors":"Arash Jalali-Sohi, L. Darki, S. Beydoun","doi":"10.17925/USN.2020.16.2.110","DOIUrl":"https://doi.org/10.17925/USN.2020.16.2.110","url":null,"abstract":"Introduction: Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease with heterogeneous age of onset, symptoms, topography, and progression. A multidisciplinary clinic (MDC) is the optimal form of healthcare delivery. We aimed to assess the demographic characteristics of, and the healthcare delivery to, patients with ALS attending an ALS MDC. Methods: A retrospective chart review of 82 patients attending our MDC was conducted. Results: Sixty percent of patients were male. Spinal-onset ALS was most common, had earlier onset, and occurred more in males. Median time from symptom onset to initial MDC visit was 18 months. More prevalent was the use of riluzole than edaravone. Percutaneous endoscopic gastrostomy (PEG) improved patient weight change (p=0.026). Conclusions: Our patient cohort further confirms observed demographic trends. More should be done to identify barriers that delay referral to specialist services. Multidisciplinary care helps capture disease characteristics and progression. PEG placement reduces weight loss and should be pursued earlier. MDCs should characterize their patient populations to evaluate, and further optimize, healthcare delivery.","PeriodicalId":90076,"journal":{"name":"US neurology","volume":"16 1","pages":"110"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67612642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Patent Foramen Ovale Closure—Addressing the Unmet Need for Reducing the Risk of Ischemic Stroke 卵圆孔未闭:降低缺血性卒中风险的未满足需求

US neurology Pub Date : 2020-01-01 DOI: 10.17925/usn.2020.16.1.54

H. Diener, B. Albers, R. Smalling

{"title":"Patent Foramen Ovale Closure—Addressing the Unmet Need for Reducing the Risk of Ischemic Stroke","authors":"H. Diener, B. Albers, R. Smalling","doi":"10.17925/usn.2020.16.1.54","DOIUrl":"https://doi.org/10.17925/usn.2020.16.1.54","url":null,"abstract":"Cryptogenic stroke—that is, stroke of an undefined origin, despite thorough investigation—is relatively common, accounting for around one-quarter of cerebral ischemic events. People under 55 years of age are relatively more likely to experience cryptogenic stroke than older individuals. In many patients, the presence of a patent foramen ovale (PFO) may contribute to the risk of cryptogenic stroke; a PFO allows dislodged venous thrombi to pass from the right atrium to the left atrium. This is the basis of paradoxical embolism, and the resulting cerebral artery occlusion may lead to stroke. Treatment to reduce the risk of recurrent cryptogenic stroke uses antithrombotic agents and, increasingly, the interventional option of PFO closure using a catheter-based closure device. Following early clinical trials, the benefit of PFO closure was relatively uncertain. Emerging evidence from longer-term studies published in recent years, however, has presented a clear case for the benefits of PFO closure in selected patients under the age of 60 years in terms of reducing risk of recurrent stroke. Treatment guidelines are being updated to reflect these findings.","PeriodicalId":90076,"journal":{"name":"US neurology","volume":"16 1","pages":"54"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67612554","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Wound Botulism in a Drug User—A Case Report and a Review of Botulism 一个吸毒者的伤口肉毒中毒——一例报告和肉毒中毒的回顾

US neurology Pub Date : 2020-01-01 DOI: 10.17925/USN.2020.16.2.116

L. Darki, Arash Jalali-Sohi, S. Beydoun

引用次数: 1

Latest Developments in Preclinical Alzheimer’s Disease 临床前阿尔茨海默病的最新进展

US neurology Pub Date : 2019-01-01 DOI: 10.17925/USN.2019.15.1.12

M. Farlow

引用次数: 0

Spinal Muscular Atrophy—Two Case Reports of Compound Heterozygosity 脊髓性肌萎缩-复合杂合性2例报告

US neurology Pub Date : 2019-01-01 DOI: 10.17925/usn.2019.15.2.97

D. S. Cooper, L. Darki, S. Beydoun

引用次数: 1